VYGR News and Press, Voyager Therapeutics Inc.

Blend Labs Inc. Class A (BLND) is expected to report $-0.02 for Q4 2025 United Natural Foods Inc. (UNFI) is expected to report $0.51 for Q2 2026 Consumer Portfolio Services Inc. (CPSS) is expected to report $0.23 for Q4 2025 Westrock Coffee Company (WEST) is expected to report $-0.1 f...

2026-03-09 16:05:21 ET Voyager Therapeutics press release ( VYGR ): Q4 GAAP EPS of -$0.46 beats by $0.07 . Collaboration revenue of $15.34M (+144.3% Y/Y) beats by $4.85M . Cash, cash equivalents and marketable securities as of December 31, 2025, were $201.7 mil...

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study us...

2026-03-03 14:22:17 ET Voyager Therapeutics, Inc. (VYGR) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 3:20 PM EST... Read the full article on Seeking Alpha For further details see: Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36t...

2025-12-04 06:30:00 ET Originally published on November 25, 2025 There have been some interesting failures recently in Alzheimer’s trials. As long-time readers will know, I consider basically all Alzheimer’s drug trials to have failed to one degree or another, and ...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

2025-11-10 08:15:00 ET More on Voyager Therapeutics Voyager Therapeutics, Inc. (VYGR) Presents at Citi's Biopharma Back to School Conference - Slideshow Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript Seeking Alpha&...

- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $2...

CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology compan...

2025-09-02 18:23:41 ET Voyager Therapeutics, Inc. (VYGR) Citi's Biopharma Back to School Conference September 2, 2025 4:00 PM EDT... Read the full article on Seeking Alpha For further details see: Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School ...